| Author | Year | NLR | CVD | Non-CVD | OR (95%CI) | Cutoff | Low NLR | High NLR | Low NLR | High NLR |
| Coronary artery disease | | | | | | | |
| Sari [13] | 2015 | 2.30 | - | - | - | - | 1.51 (1.15, 2.00) | Aygün [14] | 2015 | 2.05 | 40 | 56 | 109 | 87 | 1.75 (1.07, 2.88) | Acar [15] | 2015 | 2.25 | - | - | - | - | 2.30 (1.19, 4.43) | Verdoia [16] | 2015 | 2.03 | 349 | 783 | 103 | 137 | 1.69 (1.27, 2.24) | Yu [18] | 2016 | 2.41 | - | - | - | - | 1.69 (1.48,1.94) | Verdoia [20] | 2016 | 1.80 | 682 | 2172 | 251 | 633 | 1.26 (1.07, 1.49) | Chittawar [23] | 2017 | 2.60 | 2 | 8 | 197 | 58 | 13.59 (2.81, 65.76) | Guo [24] | 2017 | 2.45 | - | - | - | - | 2.01 (0.88, 4.63) | Sharma [25] | 2017 | 2.13 | - | - | - | - | 1.49 (0.94, 2.37) |
| Pooled OR (95% CI) | | | | | | | 1.62 (1.38, 1.91) |
| Acute coronary syndrome | | | | | | | |
| Yu [18] | 2016 | 2.42 | - | - | - | - | 1.65 (1.43, 1.90) | Zazula [27] | 2008 | 5.70 | - | - | - | - | 4.51 (1.51, 13.45) | Nordestgaard [28] | 2010 | - | - | - | - | - | 1.52 (0.83, 2.79) | Caimi [29] | 2015 | 2.19 | 39 | 43 | 11 | 12 | 1.01 (0.40, 2.55) | Göktaş [32] | 2018 | 3.0 | 40 | 23 | 26 | 11 | 1.36 (0.57, 3.25) |
| Pooled OR (95% CI) | | | | | | | 1.64 (1.30-2.05) |
| Stroke | | | | | | | |
| Saliba [33] | 2015 | 3.15 | 649 | 332 | 24049 | 7882 | 1.56 (1.36, 1.79) | Ertas [34] | 2013 | 3.17 | 20 | 19 | 64 | 23 | 2.64 (1.20, 5.81) | Akil [36] | 2014 | - | - | - | - | - | 8.95 (1.88, 42.61) | Suh [39] | 2017 | 3.00 | 23,530 | 219 | 936 | 23 | 2.64 (1.71, 4.08) |
| Pooled OR (95% CI) | | | | | | | 2.36 (1.44, 3.89) |
| Composite outcomes | | | | | | | |
| Tsai [43] | 2007 | - | - | - | - | - | 1.52 (0.96, 2.40) | Azab [44] | 2013 | 2.40 | 20 | 206 | 23 | 89 | 2.66 (1.39, 5.09) | Solak [45] | 2013 | 2.80 | 3 | 63 | 109 | 50 | 45.78 (13.71, 152.85) | Abe [46] | 2015 | 3.67 | 10 | 26 | 33 | 17 | 5.05 (1.98, 12.86) | Quiros-Roldan [47] | 2016 | 1.20 | 22 | 90 | 1091 | 2251 | 1.98 (1.24, 3.18) |
| Pooled OR (95% CI) | | | | | | | 3.86 (1.73, 8.64) |
|
|
CI, confidence interval; CVD, cardiovascular disease; NLR, neutrophil lymphocyte ratio; OR, odds ratio.
|